A5006610284- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer, Stress, Anesthesia, and Immune Response
- Radiomics and Machine Learning in Medical Imaging
- Glioma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Immunodeficiency and Autoimmune Disorders
- Ferroptosis and cancer prognosis
- Ovarian function and disorders
- Chronic Lymphocytic Leukemia Research
- Reproductive Biology and Fertility
- Blood disorders and treatments
- Platelet Disorders and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- PARP inhibition in cancer therapy
- Autophagy in Disease and Therapy
- Neutropenia and Cancer Infections
- Multiple and Secondary Primary Cancers
Centre Hospitalier de Luxembourg
2012-2024
Institut Gustave Roussy
2009-2011
Hôpitaux Iris Sud
2011
International Drug Development Institute (Belgium)
2011
Institut Jules Bordet
2011
Clinique Saint Pierre
2011
Hospital of Prato
2009
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor metastasis pairs: 252 targeted gene sequencing, 152 RNA 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 MEN1 somatic mutations. Metastases were enriched ESR1, PTEN, CDH1, PIK3CA, RB1 mutations; MDM4 MYC amplifications; ARID1A deletions. An increase clonality was...
Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial Principle (TOP) study, which patients with estrogen receptor (ER) -negative tumors were treated anthracycline (epirubicin) monotherapy, was specifically designed evaluate the value topoisomerase II-α (TOP2A) and develop a gene expression signature identify those who do not benefit from anthracyclines.The TOP trial included 149 patients, 139 whom evaluable for...
Chronic lymphocytic leukemia (CLL) cells are often affected by genomic aberrations targeting key regulatory genes. Although fludarabine is the standard first line therapy to treat CLL, only few data available about resistance of B this purine nucleoside analog in vivo. Here we sought increase our understanding action and describe mechanisms leading We performed an analysis aberrations, gene expression profiles, microRNAs CLL blood lymphocytes isolated during course patients' treatment with...
Long-term granulocyte-colony stimulating factor treatment has been shown to be safe and effective in severe chronic neutropenia patients. However, data on its use during pregnancy are limited. To address this issue, we analyzed all pregnancies reported the European branch of Severe Chronic Neutropenia International Registry since 1994. A total 38 21 women with (16 10 congenital, 6 cyclic, 12 5 idiopathic neutropenia) were reported. Granulocyte-colony was administered throughout 16 for at...
For 15 years, an overflowing literature has been published about MDR-1 gene expression in tumor cell lines and cancerous tissues at various stages of disease treatment (chemotherapy-naive, during relapse). However, the clinical significance this particular feature, if it seemed obvious 1980s as a factor responsible for development chemoresistance, is currently reconsidered. seems to be, least some instances, hallmark aggressiveness chemoresistance rather than its cause, mechanisms which are...
Triple-negative subtype of breast cancer (TNBC) is hallmarked by frequent disease relapse and shows highest mortality rate. Although PD-1/PD-L1 immune checkpoint blockades have recently shown promising clinical benefits, the overall response rate remains largely insufficient. Hence, alternative therapeutic approaches are warranted. Given immunosuppressive properties CD73-mediated adenosine release, CD73 blocking emerging as attractive strategies in immunotherapy. Understanding precise...
523 Background: Anthracycline-based regimens are among the most active and used chemotherapies in BC. Here, we report results of prospective TOP trial ( NCT00162812 ) which was specifically designed to identify markers response/resistance preoperative epirubicin (100 mg/m 2 q2 or q3wks) estrogen receptor-negative (ER-) BC patients. Methods: Using pre-epirubicin biopsies, analyzed TOP2A by fluorescence situ hybridization (Abbott triple probe) immunohistochemistry (KiS1) generated gene...
Objective: This pilot randomized controlled trial (RCT) aimed at evaluating the feasibility and potential efficacy of a motivational interviewing (MI) intervention to increase physical activity (PA) behavior in cancer patients. Methods: Participants were randomly assigned an experimental group with standard care plus 12 MI sessions within weeks or control only. The number recruited participants modality recruitment recorded describe reach study. acceptability study was estimated using...
Abstract Programmed death‐ligand 1 (PD‐L1) expression has long been used as a biomarker to stratify patients with cancer who will benefit from anti‐PD‐1/PD‐L1 immunotherapy. However, the use of PD‐L1 guide treatment decisions recently called into question due its dynamic and heterogeneous within each tumor among different tumors well during cell plasticity. Therefore, understanding molecular basis would enable delineating value reliable in clinic. Here, we provide our perspective on...
Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial Principle (TOP) study, which patients with estrogen receptor (ER)-negative tumors were treated anthracycline (epirubicin) monotherapy, was specifically designed evaluate the value topoisomerase II-alpha (TOP2A) and develop a gene expression signature identify those who do not benefit from anthracyclines. Here we describe details contents quality controls for...
<p>Association of RCB with clinicopathologic features and treatment in all patients. <b>A–C,</b> Forest plots showing the association RCB, either as class or continuous score, standard variables (A), sTILs (continuous %; B), (categorical; C) evaluated by regression analyses Analyses were performed on subset patients diagnosed treated at UZ Leuven, Belgium.</p>
<p>sTIL scoring and its association with clinicopathological features in all patients. <b>A,</b> Distribution of sTIL (continuous) the entire cohort subtypes. <b>B,</b> (category) <b>C,</b> Forest plots showing (categorical) standard clinicopathologic variables evaluated by regression analyses patients.</p>
<p>sTIL scoring and its association with clinicopathological features in all patients. <b>A,</b> Distribution of sTIL (continuous) the entire cohort subtypes. <b>B,</b> (category) <b>C,</b> Forest plots showing (categorical) standard clinicopathologic variables evaluated by regression analyses patients.</p>
<div>Abstract<p>Inflammatory breast cancer (IBC) is a rare (1%–5%), aggressive form of cancer, accounting for approximately 10% mortality. In the localized setting, standard care neoadjuvant chemotherapy (NACT) ± anti-HER2 therapy, followed by surgery. Here we investigated associations between clinicopathologic variables, stromal tumor-infiltrating lymphocytes (sTIL), and pathologic complete response (pCR), prognostic value pCR. We included 494 patients with IBC treated NACT from...
<p>Supplementary Figure 1 shows examples of sTIL scoring in skin on H&E images.</p>
<p>Association of pCR with OS. <b>A,</b> Kaplan–Meier curves OS according to pCR. <b>B,</b> Forest plots showing the association and standard clinicopathologic treatment variables quantified by Cox regression.</p>
<p>Association of pCR with clinicopathologic features and treatment in all patients. <b>A–C,</b> Forest plots showing the association standard variables (A), sTILs (continuous %; B), (categorical; C) evaluated by regression analyses patients.</p>